Abbott Biosimilars Drive Cancer Treatment Access in Emerging Markets
SHERIDAN, WYOMING - April 13, 2026 - Abbott's biosimilars medicines business is accelerating access to advanced biologic cancer therapies across emerging markets, where today only 0.1% of new biologic medicines are launched compared to 2%-3% penetration in developed markets. The disparity matters because emerging-market countries account for 57% of new cancer diagnoses globally and 65% of cancer deaths each year. Biosimilars - high-quality copies of approved biologic medicines with no meaningful difference in quality, safety, or efficacy - represent Abbott's core mechanism for closing that gap. With global cancer cases projected to climb from 20 million annually to more than 35 million by 2050, the business and public health stakes of biosimilar adoption are substantial.